Royal Bank of Canada
VIRX

Royal Bank of Canada’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Royal Bank of Canada’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$5K – 7369
2024
Q3 		$5K Buy
20,000
+19,543
+4,276% +$7.17K ﹤0.01% 6529
2024
Q2 		$0 Sell
457
-1,611
-78% -$1.27K ﹤0.01% 7660
2024
Q1 		$2K Sell
2,068
-8,437
-80% -$6.16K ﹤0.01% 6726
2023
Q4 		$6K Buy
10,505
+9,004
+600% +$5.53K ﹤0.01% 6632
2023
Q3 		$1K Buy
1,501
+1,205
+407% +$1.64K ﹤0.01% 6972
2023
Q2 		$0 Sell
296
-2,711
-90% -$3.88K ﹤0.01% 7754
2023
Q1 		$5K Buy
3,007
+3,000
+42,857% +$5.45K ﹤0.01% 6589
2022
Q4 		$0 Buy
+7
New +$20 ﹤0.01% 7844
2022
Q2 		– Sell
-2,227
Closed -$11K – 7810
2022
Q1 		$11K Sell
2,227
-135,380
-98% -$408K ﹤0.01% 6920
2021
Q4 		$502K Sell
137,607
-44,712
-25% -$239K ﹤0.01% 4442
2021
Q3 		$1.46M Sell
182,319
-12,207
-6% -$120K ﹤0.01% 3344
2021
Q2 		$2.21M Buy
194,526
+192,484
+9,426% +$1.93M ﹤0.01% 2975
2021
Q1 		$19K Buy
2,042
+1,997
+4,438% +$20.8K ﹤0.01% 6460
2020
Q4 		$0 Sell
45
-29
-39% -$151 ﹤0.01% 7343
2020
Q3 		$0 Hold
74
– – ﹤0.01% 7005
2020
Q2 		$1K Buy
74
+1
+1% +$15 ﹤0.01% 6504
2020
Q1 		$1K Buy
+73
New +$1.58K ﹤0.01% 6515
2019
Q4 		– Sell
-44
Closed -$1K – 7195
2019
Q3 		$1K Buy
44
+20
+83% +$577 ﹤0.01% 6538
2019
Q2 		$1K Sell
24
-1
-4% -$39 ﹤0.01% 6758
2019
Q1 		$1K Buy
25
+1
+4% +$23 ﹤0.01% 6696
2018
Q4 		$0 Sell
24
-2
-8% -$82 ﹤0.01% 7198
2018
Q3 		$2K Buy
26
+2
+8% +$152 ﹤0.01% 6543
2018
Q2 		$2K Hold
24
– – ﹤0.01% 6280
2018
Q1 		$2K Hold
24
– – ﹤0.01% 6137
2017
Q4 		$3K Buy
+24
New +$2.25K ﹤0.01% 6217
2017
Q3 		– Hold
0
– – – 7042
2017
Q1 		– Sell
-3
Closed – – 6863
2016
Q4 		$0 Sell
3
-5
-63% -$696 ﹤0.01% 6820
2016
Q3 		$1K Sell
8
-46
-85% -$6.49K ﹤0.01% 6320
2016
Q2 		$6K Sell
54
-4
-7% -$443 ﹤0.01% 5903
2016
Q1 		$7K Sell
58
-49
-46% -$7.43K ﹤0.01% 5850
2015
Q4 		$20K Sell
107
-42
-28% -$7.86K ﹤0.01% 5718
2015
Q3 		$26K Buy
149
+96
+181% +$34.6K ﹤0.01% 5457
2015
Q2 		$33K Sell
53
-230
-81% -$122K ﹤0.01% 5445
2015
Q1 		$146K Buy
283
+244
+626% +$123K ﹤0.01% 4412
2014
Q4 		$21K Sell
39
-518
-93% -$233K ﹤0.01% 5394
2014
Q3 		$836K Sell
557
-456
-45% -$660K ﹤0.01% 2989
2014
Q2 		$1.39M Buy
1,013
+918
+966% +$1.07M ﹤0.01% 2558
2014
Q1 		$132K Sell
95
-10
-10% -$11.6K ﹤0.01% 4388
2013
Q4 		$105K Sell
105
-49
-32% -$50.7K ﹤0.01% 4547
2013
Q3 		$160K Sell
154
-23
-13% -$24.6K ﹤0.01% 4219
2013
Q2 		$194K Buy
+177
New +$197K ﹤0.01% 3917

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's VIRX Position: Q4 2024 in Review

Royal Bank of Canada sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 20,000 shares — an estimated $5K sold.

Royal Bank of Canada first reported a position in VIRX in Q2 2013 and held it in 40 quarters. The position peaked at $2.21M in Q2 2021. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

  • Royal Bank of Canada reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 20,000 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $5K.
  • Royal Bank of Canada first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 40 quarters.
  • Royal Bank of Canada's Viracta Therapeutics, Inc. Common Stock position peaked at $2.21M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.